Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student health in the classroom and on the athletic field.

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...